Skip to main content
Top
Published in: Journal of Neurology 1/2013

01-01-2013 | Original Communication

Estimation of Parkinson’s disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach

Authors: O. Chillag-Talmor, N. Giladi, S. Linn, T. Gurevich, B. El-Ad, B. Silverman, N. Friedman, C. Peretz

Published in: Journal of Neurology | Issue 1/2013

Login to get access

Abstract

The aim of this work was to estimate in an incident cohort of pharmacy-based PD patients the survival of men and women accounting for age at treatment initiation and to compare their gender-specific survival with that of the general Israeli population. A population-based cohort of 4,848 incident pharmacy-based PD cases with definite/probable/possible certainty was previously identified using a drug-tracer approach for 1999–2008. Survival analysis was performed for two time scales: survival after treatment initiation (disease duration), and life-time survival (life expectancy). Kaplan–Meier curves and Cox regressions were used to compare survival across gender. Gender-specific SMRs were calculated from national rates and were compared using Poisson regression. During the follow-up from first purchase of any anti-parkinsonian drug (mean 4.0 ± 2.6 years, range 2 months–10 years), 1,266 (26 %) of the cases died. Younger age at first anti-parkinsonian drug purchase and female gender were associated with increased survival after treatment initiation (HR = 1.089, 95 % CI 1.080–1.098 for 1-year age increase; HR = 0.716, 95 % CI 0.640–0.800, females vs. males). Life-time survival increased with older age at first anti-parkinsonian drug purchase and female gender (HR = 0.759, 95 % CI 0.746–0.771 for 1-year age increase; HR = 0.694, 95 % CI 0.621–0.776, females vs. males). Sensitivity analysis on a sub-cohort of definite cases (n = 2501) yielded similar results. In comparison to the general Israeli population, mortality among pharmacy-based PD patients was significantly increased (SMRmen = 1.69, 95 % CI 1.57–1.81, SMRwomen = 1.49, 95 % CI 1.37–1.62), differently between genders (p < 0.01). Female gender was associated with longer, perhaps more benign disease course, and longer life expectancy. Earlier age at anti-parkinsonian drug initiation increased disease duration, but was associated with shorter life expectancy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ishihara LS, Cheesbrough A, Brayne C, Schrag A (2007) Estimated life expectancy of Parkinson’s patients compared with the UK population. J Neurol Neurosurg Psychiatry 78:1304–1309PubMedCrossRef Ishihara LS, Cheesbrough A, Brayne C, Schrag A (2007) Estimated life expectancy of Parkinson’s patients compared with the UK population. J Neurol Neurosurg Psychiatry 78:1304–1309PubMedCrossRef
2.
go back to reference Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV (2006) Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord 21:1221–1225PubMedCrossRef Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV (2006) Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord 21:1221–1225PubMedCrossRef
3.
go back to reference Chillag-Talmor O, Giladi N, Linn S et al (2011) Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson’s disease in a large Israeli population. J Parkinson’s Dis 1:35–47 Chillag-Talmor O, Giladi N, Linn S et al (2011) Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson’s disease in a large Israeli population. J Parkinson’s Dis 1:35–47
4.
go back to reference Israel Central Bureau of Statistics (2010). Complete life tables of Israel, 2004–2008. Jerusalem Israel Central Bureau of Statistics (2010). Complete life tables of Israel, 2004–2008. Jerusalem
5.
go back to reference Taeger D, Sun Y, Keil U, Straif K (2000) A stand-alone windows applications for computing exact person-years, standardized mortality ratios and confidence intervals in epidemiological studies. Epidemiology 11:607–608PubMedCrossRef Taeger D, Sun Y, Keil U, Straif K (2000) A stand-alone windows applications for computing exact person-years, standardized mortality ratios and confidence intervals in epidemiological studies. Epidemiology 11:607–608PubMedCrossRef
6.
go back to reference Elbaz A, Bower JH, Peterson BJ et al (2003) Survival study of Parkinson disease in Olmsted County Minnesota. Arch Neurol 60:91–96PubMedCrossRef Elbaz A, Bower JH, Peterson BJ et al (2003) Survival study of Parkinson disease in Olmsted County Minnesota. Arch Neurol 60:91–96PubMedCrossRef
7.
go back to reference Louis ED, Bennett DA (2007) Mild Parkinsonian signs: an overview of an emerging concept. Mov Disord 22:1681–1688PubMedCrossRef Louis ED, Bennett DA (2007) Mild Parkinsonian signs: an overview of an emerging concept. Mov Disord 22:1681–1688PubMedCrossRef
8.
go back to reference Forsaa EB, Larsen JP, Wentzel-Larsen T et al (2010) What predicts mortality in Parkinson’s disease? A prospective population-based long-term study. Neurology 75:1270–1276PubMedCrossRef Forsaa EB, Larsen JP, Wentzel-Larsen T et al (2010) What predicts mortality in Parkinson’s disease? A prospective population-based long-term study. Neurology 75:1270–1276PubMedCrossRef
9.
go back to reference Shulman LM, Bhat V (2006) Gender disparities in Parkinson’s disease. Expert Rev Neurother 6:407–416PubMedCrossRef Shulman LM, Bhat V (2006) Gender disparities in Parkinson’s disease. Expert Rev Neurother 6:407–416PubMedCrossRef
10.
go back to reference Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2006) Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord 21:1002–1007PubMedCrossRef Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2006) Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord 21:1002–1007PubMedCrossRef
11.
go back to reference Guttman M, Slaughter PM, Theriault ME, DeBoer DP (2001) Naylor CD Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 57(12):2278–2282PubMedCrossRef Guttman M, Slaughter PM, Theriault ME, DeBoer DP (2001) Naylor CD Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 57(12):2278–2282PubMedCrossRef
Metadata
Title
Estimation of Parkinson’s disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach
Authors
O. Chillag-Talmor
N. Giladi
S. Linn
T. Gurevich
B. El-Ad
B. Silverman
N. Friedman
C. Peretz
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 1/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6584-5

Other articles of this Issue 1/2013

Journal of Neurology 1/2013 Go to the issue